BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 20430977)

  • 1. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
    Devanand DP; Mikhno A; Pelton GH; Cuasay K; Pradhaban G; Dileep Kumar JS; Upton N; Lai R; Gunn RN; Libri V; Liu X; van Heertum R; Mann JJ; Parsey RV
    J Geriatr Psychiatry Neurol; 2010 Sep; 23(3):185-98. PubMed ID: 20430977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 18F-FDG and PiB PET in cognitive impairment.
    Lowe VJ; Kemp BJ; Jack CR; Senjem M; Weigand S; Shiung M; Smith G; Knopman D; Boeve B; Mullan B; Petersen RC
    J Nucl Med; 2009 Jun; 50(6):878-86. PubMed ID: 19443597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
    Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
    Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF
    Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.
    Cohen AD; Price JC; Weissfeld LA; James J; Rosario BL; Bi W; Nebes RD; Saxton JA; Snitz BE; Aizenstein HA; Wolk DA; Dekosky ST; Mathis CA; Klunk WE
    J Neurosci; 2009 Nov; 29(47):14770-8. PubMed ID: 19940172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.
    Zhang S; Han D; Tan X; Feng J; Guo Y; Ding Y
    Int J Clin Pract; 2012 Feb; 66(2):185-98. PubMed ID: 22257044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.